By Stephen Nakrosis 
 

The U.S. Food and Drug Administration on Friday said it gave approval to Genentech Inc.'s Evrysdi as a treatment for spinal muscular atrophy.

The FDA said Evrysdi, or risdiplam, was approved to "treat patients two months of age and older with spinal muscular atrophy, a rare and often fatal genetic disease affecting muscle strength and movement," and added, "This is the second drug and the first oral drug approved to treat this disease."

The FDA also said "The efficacy of Evrysdi for the treatment of patients with infantile-onset and later-onset SMA was evaluated in two clinical studies."

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

August 07, 2020 15:02 ET (19:02 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Roche (QX) Charts.